Fmr LLC Acquires 12,241 Shares of Catalent, Inc. (NYSE:CTLT)

Fmr LLC lifted its position in shares of Catalent, Inc. (NYSE:CTLT) by 4.8% during the third quarter, Holdings Channel reports. The firm owned 265,369 shares of the company’s stock after acquiring an additional 12,241 shares during the period. Fmr LLC’s holdings in Catalent were worth $16,073,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in CTLT. Millennium Management LLC increased its holdings in Catalent by 129.2% during the second quarter. Millennium Management LLC now owns 4,079,964 shares of the company’s stock worth $229,416,000 after buying an additional 2,299,784 shares during the last quarter. Bank of Montreal Can increased its holdings in Catalent by 181.5% during the third quarter. Bank of Montreal Can now owns 1,813,167 shares of the company’s stock worth $109,388,000 after buying an additional 1,169,044 shares during the last quarter. ING Groep NV increased its stake in shares of Catalent by 162.5% in the third quarter. ING Groep NV now owns 1,130,504 shares of the company’s stock worth $68,475,000 after purchasing an additional 699,851 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund purchased a new position in shares of Catalent in the second quarter worth about $29,172,000. Finally, Mizuho Markets Americas LLC purchased a new position in shares of Catalent in the third quarter worth about $30,285,000.

Wall Street Analysts Forecast Growth

CTLT has been the subject of several recent research reports. William Blair reiterated a “market perform” rating on shares of Catalent in a research note on Tuesday, September 3rd. Baird R W cut shares of Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. StockNews.com cut shares of Catalent from a “hold” rating to a “sell” rating in a research note on Tuesday. Finally, Robert W. Baird reaffirmed a “neutral” rating and set a $63.50 price objective on shares of Catalent in a research note on Tuesday, September 24th. One analyst has rated the stock with a sell rating and seven have assigned a hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $63.40.

Catalent Trading Down 0.2 %

Shares of CTLT opened at $62.26 on Wednesday. The firm has a market cap of $11.30 billion, a price-to-earnings ratio of -27.55, a PEG ratio of 2.46 and a beta of 1.15. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.96 and a current ratio of 2.51. Catalent, Inc. has a fifty-two week low of $36.74 and a fifty-two week high of $62.50. The firm has a 50 day moving average price of $60.15 and a 200-day moving average price of $58.85.

Catalent (NYSE:CTLT) last issued its earnings results on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.18). Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The firm had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.06 billion. During the same period in the previous year, the firm earned ($0.10) earnings per share. The firm’s quarterly revenue was up 4.2% compared to the same quarter last year. As a group, equities research analysts forecast that Catalent, Inc. will post 0.84 earnings per share for the current year.

Insider Buying and Selling at Catalent

In other news, insider David Mcerlane sold 1,994 shares of the company’s stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $59.97, for a total value of $119,580.18. Following the sale, the insider now directly owns 36,304 shares of the company’s stock, valued at $2,177,150.88. This represents a 5.21 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Michelle R. Ryan sold 2,800 shares of the company’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $59.70, for a total transaction of $167,160.00. Following the completion of the sale, the director now directly owns 10,835 shares in the company, valued at $646,849.50. This represents a 20.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 5,114 shares of company stock valued at $305,931. 0.31% of the stock is currently owned by company insiders.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.